Fractionated stereotactic radiotherapy for uveal melanoma: Long‐term outcome and control rates. Issue 5 (16th September 2021)

• Record Type: Journal Article
• Authors: van Beek, Jackelien G. M.; van Rij, Caroline M.; Baart, Sara J.; Yavuzyigitoglu, Serdar; Bergmann, Michael J.; Paridaens, Dion; Naus, Nicole C.; Kiliç, Emine
• Is Part Of: Acta ophthalmologica. Volume 100:Issue 5(2022)
• Page Start: 511
• Page End: 519
• Publication Date: 2021-09-16
• Subjects: fractionated stereotactic radiotherapy -- local tumour control -- side‐effects -- uveal melanoma; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1111/aos.15029
• Languages: English
• ISSNs: 1755-375X

Abstract

Abstract: Purpose: The aim of our study is to evaluate local tumour control rates, radiation side‐effects, visual preservation and disease‐free survival (DFS) of uveal melanoma (UM) patients treated with fractionated stereotactic radiotherapy (fSRT). Methods: A retrospective study of UM patients, who were treated with fSRT ( N = 189), was performed by the Rotterdam Ocular Melanoma Study group (ROMS), the Netherlands, between 1999 and 2014 with a follow‐up of at least 5 years. Results: The 1‐, 3‐, 5‐, 10‐ and 15‐year local tumour control rates were as follows: 99.4%, 92.8%, 92.2%, 89.3% and 89.3%, respectively. Cataract (67.8%) was the most common side‐effect of fSRT followed by retinopathy (35.1%), maculopathy (23.8%), vitreous haemorrhage (20.1%), neovascular glaucoma (NVG) (20.0%) and optic neuropathy (12.4%). Patients with anterior located UMs developed cataract more frequently (p = 0.047, multivariable analysis). By multivariable analysis, significant factors for secondary enucleation were tumour recurrence (p < 0.001) and NVG (p < 0.001). In multivariable analysis, risk factors for a worse DFS were larger UM (p = 0.024) and tumours with subretinal fluid (SRF) at baseline (p = 0.038). The 5‐year DFS was 77.0% and the best corrected visual acuity decreased significantly after treatment. After 5 years, 22.0% of patients and after 10 years 17.6% of patients had a visual acuity of ≤0.3 logMAR. Conclusion: Fractionated stereotactic radiotherapy is a good treatment option for small‐, medium‐ and large‐sized tumours with 5‐year local tumour control of 92.2%. After 5 years, 22.0% of the patients had a good vision. Independently of tumour location, the visual acuity decreased significantly after treatment. Overall, the 5‐year DFS was 77.0%.